S. 990 was signed into law last week. At first glance, it looks like it extends the life of Small Business Administration programs that are near and dear to the bottom line of many small biotechs. But somewhere along its pat through the Senate, the bill was stripped of the language that would have extended the Small Business Innovation Research (SBIR) program through Sept. 30, 2012. In its place are a few short paragraphs renewing the Patriot Act. But the title of the bill remains “To provide for an additional temporary extension of programs under the Small Business Act and...

Facebook is forcing biotechs to get out of the neighborhood or get more friendly – a move that could set drug companies up for a potential run-in with the regulatory police.

WASHINGTON – Small biotechs waiting for Congress to breathe new life into the Small Business Innovation Research (SBIR) program will have to wait a little longer.

Employees could be blowing their whistles earlier and a lot more often under the final rules passed by the SEC Wednesday.

WASHINGTON – Citing as their prime evidence Sanofi's strategy to prevent approval of Lovenox biosimilars, two senators are building a case for more disclosure of biopharma's financial ties with nonprofit medical groups, especially when those nonprofits intervene on drug approvals and safety issues.

As soon as the bell rang Monday with the FDA's approval of Incivek as the next hepatitis C contender, Vertex Pharmaceutical Inc. was ready to throw some punches to claim its share of the market.

WASHINGTON – Threats of terrorist attacks in the wake of the death of Osama bin Laden and the reality of immense natural disasters are creating a sense of urgency as government officials recognize that the U.S. is "woefully behind" in its capability to rapidly produce vaccines and develop medical countermeasures (MCM).

WASHINGTON – Google searches and all the chatter on social networking sites could become part of the adverse event analyses the FDA uses to gauge the safety of drugs and biologics once they're on the market.

Global in perspective, Aeras, a nonprofit product development partnership (PDP), is singular in its focus – developing the first new preventive tuberculosis (TB) vaccines in nearly a century.

RxBio Inc. has been hard at work building the funding bridge it's counting on to take its lead candidate, RX100, down the home stretch toward approval.